Mantle cell lymphoma (MCL) remains one of the more challenging B-cell non-Hodgkin lymphomas, distinguished by its aggressive clinical course and complex molecular signature. Recent investigations have ...

Translocations are chromosomal "cut and paste" errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...

BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation The combination of the Bruton tyrosine ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We already know CAR T, cellular therapy, ...

Beloved Australian actor, Magda Szubanski, has revealed she’s been diagnosed with a “very rare, very aggressive, very serious” blood cancer called mantle cell lymphoma. In a post on social media on ...

In patients with relapsed/refractory mantle cell lymphoma (MCL) who were naive to Bruton tyrosine kinase inhibitor (BTKi) therapy, brexucabtagene autoleucel (brexu-cel) was associated with high ...